Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2006

View Archived Issues

Unique IL-6 immunosuppressive activity of sanglifehrin A

Platinum-based compound with improved cell absorption designed at VCU

Serono completes phase III trial of recombinant human growth hormone in HARS

Phase IIb program planned for long-acting beta2 agonist GSK-159797

Vertex and CFFT extend cystic fibrosis research collaboration

Stem Cell Therapeutics updates progress of NTx-265

Takeda's SYR-322 begins phase III for diabetes

ATL-962 for obesity and related disease begins phase II in Japan

Phase II/III trial investigates defibrotide to prevent veno-occlusive disease

Dendreon focuses resources on Provenge

Shire to respond to NICE's review of Alzheimer's disease treatments

FDA accepts Factive filing for five-day CAP, refuses filing for ABS

Ushercell studied for treatment of bacterial vaginosis in new phase II trial

Leptin's antidepressant potential

MC160 facilitates persistent poxvirus infection but may be useful for inflammatory syndromes

Fast track designation for alfimeprase in acute peripheral arterial occlusion

Sosei withdraws Eligard submission in Japan

Japanese approval for Urief

Paxil approved for obsessive compulsive disorder in Japan

Targeting JNK to prevent AAA pathogenesis

Therapeutic agents for HIV infection reported in recent patent literature

Novel agents claimed for thrombotic disorders in recent patents

Novartis discloses novel diagnostic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.